Curated News
By: NewsRamp Editorial Staff
May 07, 2025
Clene Inc. to Participate in Global Conference; CEO Available for Meetings
TLDR
- Clene (NASDAQ: CLNN) to participate in D. Boral Capital Inaugural Global Conference, offering exclusive one-on-one meetings for potential investors.
- Clene focuses on improving mitochondrial health and protecting neuronal function through their investigational therapy CNM-Au8® for neurodegenerative diseases.
- Clene's work aims to enhance central nervous system cells' survival and function, potentially revolutionizing the treatment of neurodegenerative diseases for a better tomorrow.
- Clene's participation in the conference showcases cutting-edge research in neurodegenerative disease treatment, providing hope for patients worldwide.
Impact - Why it Matters
This news matters as it highlights Clene's involvement in a major conference and the potential of its innovative therapy for neurodegenerative diseases. Investors and individuals interested in advancements in healthcare should take note of Clene's developments.
Summary
Clene (NASDAQ: CLNN) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. President and CEO Rob Etherington will be available for meetings from 9 a.m. to 3 p.m. ET.
Clene Inc., a biopharmaceutical company, focuses on improving mitochondrial health to treat neurodegenerative diseases. Its investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. to Participate in Global Conference; CEO Available for Meetings
